Nebraska State Senator

Carolyn Bosn Authored & Sponsored Legislation

Session

Primary Sponsor of Legislation

NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB150

Introduced
1/13/25  
Change the habitual criminal sentencing enhancement
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB191

Introduced
1/13/25  
Change provisions relating to unlawful interference with telecommunications under the One-Call Notification System Act
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB205

Introduced
1/14/25  
Provide requirements for admissibility of evidence relating to medical expenses, require disclosures by plaintiffs seeking damages for such expenses, and provide a cap on noneconomic damages in certain civil actions against commercial motor vehicle carriers
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB387

Introduced
1/17/25  
Redefine a term under the Nebraska Treatment and Corrections Act
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB4

Introduced
1/9/25  
Adopt the Telecommunications Exchange Deregulation Act
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB464

Introduced
1/21/25  
Create the offense of organized retail crime and provide penalties under the Nebraska Criminal Code
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB465

Introduced
1/21/25  
Change provisions relating to annual fees and eliminate requirements for the use of a personal vehicle for transportation network companies
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB466

Introduced
1/21/25  
Redefine a term under the Nebraska Juvenile Code
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB470

Introduced
1/21/25  
Refer
1/23/25  
Provide for attorneys to make unsworn declarations under penalty of perjury in lieu of sworn declarations
NE

Nebraska 2025-2026 Regular Session

Nebraska Legislature Bill LB5

Introduced
1/9/25  
Provide immunity for administration of naloxone or other federally approved opioid antagonists